secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2023-09-06T23:59:59+00:00
Accession:  0000950170-23-046722
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen receives Health Canada clearance to begin Phase 1 study of PGN-EDODM1 in DM1; FDA grants Orphan Drug Designation
--------------------------------------------------------------------------------

- Health Canada issued No Objection Letter for CTA to start FREEDOM-DM1 Phase 1 trial of PGN-EDODM1 in myotonic dystrophy type 1.
- FDA granted Orphan Drug Designation to PGN-EDODM1 for the treatment of DM1.
- Phase 1 study is a randomized, placebo-controlled, SAD study enrolling ~24 adults; dose escalation from 5 mg/kg to 10 mg/kg then 20 mg/kg.
- Initial results from the FREEDOM-DM1 study are expected in 2024.
- FDA clinical hold on US IND for PGN-EDODM1 remains; company continues working to resolve it.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000095017023046722/0000950170-23-046722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000095017023046722/pepg-20230906.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-046722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer